O I P E Receipt date: 09/26/2007 SEP 2 6 2007

PTO/SB/08A (09-06)
Approved for use through 07/31/2006, OMB 0651-0031

A TRADEM Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO Application Number 10/591.722 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Atsushi SAITOU (Use as many sheets as necessary) Group Art Unit Examiner Name Sheet 1 of 4 Attorney Docket Number MOEG-P100

| | | U.S. | PATENT DOCUM | ENTS | |
|-----------------------|--------------|--|--------------|--|---|
| Examiner Initials* | Cite No.1 | Document Number Publication Date | | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, |
| initials. | No. | Number- Kind Code ^{2 (# brown)} | MM-DD-YYYY | or Cited Document | Where Relevant Passages or Relevant Figures Appear |
| | | US-5,086,069 | 02-04-1992 | Klein et al. | |
| | | US-5,633,231 | 05-27-1997 | Habich et al. | |
| | | US-5,886,044 | 03-23-1999 | Widdowson et al. | |
| | | US-6,096,773 | 08-01-2000 | Scott et al. | |
| | | US-6,204,294 B1 | 03-20-2001 | Bryan et al. | |
| | | US-6,750,348 B1 | 06-15-2004 | Bridger et al. | |
| | | US-7,091,217 B2 | 08-15-2006 | Bridger et al. | |
| | | US-7,098,215 | 08-29-2006 | Yamazaki et al. | |
| | | US-7,176,227 | 02-13-2007 | Yamazaki et al. | |
| | | US-2004/0157818 A1 | 08-12-2004 | Yanaka et al. | |
| | | US-2004/0254221 A1 | 12-16-2004 | Yamazaki et al. | |

| | | | FOREIG | N PATENT DO | CUMENTS | | |
|-----------------------|--------------|----|--|--------------------------------|--|--|-----|
| Examiner Initials* | Cite No.1 | | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or | 7.0 |
| | | _ | ry Code ³ -Number-Kind Code ⁶ (if known) | | | Relevant Figures Appear | 1, |
| | | EP | 0 183 271 A2 | 06-04-1986 | Showa Denko K.K. | | _ |
| | | EP | 0 628 551 | 12-14-1994 | Shionogi & Co., Ltd. | | |
| | | EP | 0 646 598 | 04-05-1995 | Bayer AG | | V* |
| | | JP | 7-89988 | 04-04-1995 | Bayer AG | | 1. |
| | | wo | 98/006397 A1 | 02-19-1998 | Smith Kline Becham | | П |
| | | wo | 99/033787 A1 | 07-08-1999 | Kureha Corporation | | 1. |
| | | wo | 00/056729 A1 | 09-28-2000 | Anormed Inc. | | Г |
| | | wo | 00/006086 A2 | 02-10-2000 | Trustees of Columbia University in City of NY | | |
| | | wo | 01/010842 A2 | 02-15-2001 | Millennium Pharmaceuticals, Inc. | | Г |
| | | wo | 01/079168 A1 | 10-25-2001 | Kureha Chemical Industry Co., Ltd. | | 1. |

| Examiner | Date | |
|----------------------|-------------------|--|
| Signature | Considered | |
| SEMANDED. INVESTMENT | IL MOED OOD D | Control of the Contro |

"EXAMINET: Initial if reference considered, whether or not clastion is in conformance with MPEP 609. Draw the through clastion if not inconformance and not considered, include copy of this form with next communication to applicant." Applicant's unique clastion designation number (optional). "See Kints Codes of USPTO Patient Documents at www.uspids.gov or MPEP 801.04. "Enter Office that issued the document, by the two-letter code (MPEO Standard ST.3). "For Japanese patient occument, is included to the comment of the patient document. Sind of document by the appropriate symbols as inficilated on the document under VMPO Standard ST.16 if possible. "Applicant is a place a check mark here if English language transition is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO of process) an application. Confederability is governed by 38 U.S. C. 122 and 37 CFR 1.17. This collection is estimated to late 2.07 to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form androis vagogistions for reducing this burden; houside see that the Chrief Information C.U. S. Patents and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA 22313-1450.

Receipt date: 09/26/2007

Examiner

PTO/SB/08A (09-06) Approved for use through 07/31/2006. OMB 0651-0031

| Under | r the Paperwork Reduc | ion Act | of 1995, no persons a | | |
|--|--|----------------------|-----------------------|------------------------|-----------|
| U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COV Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to contains a valid OMB contro Complete if Known Application Number 10/591,722 Filing Date STATEMENT BY APPLICANT (Use as many sheets as necessary) Group Art Unit Examiner Name | nplete if Known | | | | |
| Substit | INFORMATION DISCLOSURE STATEMENT BY APPLICANT | Application Number | 10/591,722 | | |
| ĺ | | | | Filing Date | |
| l | STATEMENT BY APPLICANT | First Named Inventor | Atsushi SAITOU | | |
| | | | | Group Art Unit | |
| İ | | | | Examiner Name | |
| Sheet | 2 | of | 4 | Attorney Docket Number | MOEG-P100 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--------------|--|------------------|-------------------------------|---|--|--|
| Examiner | Cite No.1 | Document Number | Publication Date | Name of Patentee or Applicant | Pages, Columns, Lines, | | |
| Initials* | NO." | Number- Kind Code ^{2 (f known)} | MM-DD-YYYY | of Cited Document | Where Relevant Passages or Relevant Figures Appear | | |
| | | US 2004/0171638 A1 | 09-02-2004 | Bridger et al. | | | |
| | | US-2005/0165063 A1 | 07-28-2005 | Yamazaki et al. | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| | | _ | | N PATENT DO | | | _ |
|-----------------------|--------------|---------|--|--------------------------------|--|--|----------------|
| Examiner Initials* | Cite No.1 | \perp | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or | T ⁶ |
| | | Count | ry Code ³ -Number-Kind Code ⁶ (if known) | | | Relevant Figures Appear | |
| | | wo | 02/022600 A1 | 03-21-2002 | Anormed Inc. | | |
| | | wo | 02/094261 A1 | 05-20-2002 | Kureha Chemical Industry Co., Ltd. | | 7. |
| | | wo | 03/029218 A1 | 04-10-2003 | Kureha Chemical Industry Co., Ltd. | | / * |
| | | wo | 04/024697 A1 | 03-25-2004 | Kureha Chemical Industry Co., Ltd. | | <i>/</i> - |
| | | _ | | | | | |
| | - | + | | | <u> </u> | | ⊢ |
| | + | + | | | | | ┢ |
| | | 1 | | | | | |
| | | | | | | | |
| | | | | | | | |

| Signatura | | | Considered | | |
|-------------------------|-------------------------------|--------------------------------|-------------------------|-----------------------------------|---------------------------------------|
| | | | | Draw line through citation if not | |
| considered. Include cop | y of this form with next comm | unication to applicant. 'Appl | icant's unique citation | designation number (optional). | ² See Kinds Codes of USPTO |
| Patent Documents at use | au uento nov or MRED 001 07 | 4 PEnter Office that is sund t | an donument by the | hun letter ande AMBO Ctonderd | CT 3) (Cor Inconses entent |

Date

Applicant. Applicant, include only with least communication to applicant. Applicants unique claiblon designation number (opiniqual). See Kinds Codes and Parlam Documents to the who eleter code to the Wind Standard STA). For Japanes patient documents, the indication of the year of the reign of 16th and is supported and unimber of the patient document. Wind of document by the approximation of the patient of the patient of the reign of 16th and 16th an

This obsection of information is required by 31 CFR 197 and 198. The information is exquired to obtain or trains a benefit by the public which is to file (and by the USFRO) to proceed an application. Confidentially its powerined by 34 US C 22 and 37 CFR 11. The obtained is estimated to lake 2. Downton to compete, including gathering, preparing, and submitting the competed application form to the USFRO. Time will very depending upon the inclinidal case. Any comments on the amount of time your require to complete this form andrets organized the supplication form to the USFRO. The will very depending upon the inclinidal case. Any comments on the amount of time your require to complete this form andrets organized the supplication form to the USFRO. The will very depending upon the inclinidal case. Any comments on amount of time to check in formation of the USFRO. The case of the amount of time to check in formation of the USFRO. The case of the case of the case of the USFRO. The USFRO. The Case of the USFRO.
Receipt date: 09/26/2007 10591722/semallis-01626 Approved for use through 03/31/2006. OMB 0651-0031

| Under I | he Paperwork Re | eduction | Act of 1995, no persons | | formation unless it contains a valid OMB control number. |
|-----------|-----------------|----------|-------------------------|------------------------|--|
| Cubalitut | for form 1449/P | то. | | Com | plete if Known |
| Substitut | 10110111111448/ | 10 | | Application Number | 10/591,722 |
| INFO | RMATION | N DIS | CLOSURE | Filing Date | |
| STAT | EMENT I | BY A | PPLICANT | First Named Inventor | Atsushi SAITOU |
| | | | | Group Art Unit | |
| (use | as many sh | eets as | necessary) | Examiner Name | |
| Sheet | 3 | of | 4 | Attorney Docket Number | MOEG-P100 |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|--|----------------|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, sympositim, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | MOLINO, M. et al., "CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2," Biochimica et Biophysica Acta (BBA), Molecular Basis of Disease, vol. 1500, pp 227-240 (2000) | |
| | | Saishin Iqaku, Vol. 53, No. 9, pp. 2031-2038 (1998) with English translation of abstract | |
| | | Nikkei Science, Oct., p. 26-37 (1998) with English version Bartlett, John G. et al, "Improving HIV Therapy," Scientific American, pp 84-89 (July 1998) | |
| | | Molecular Medicine, Vol. 36, No. 9, pp. 1012-1017 (1999) with English translation of abstract | |
| | | Nikkei Science, Oct., pp. 42-49 (1998) with English version Baltimore, David et al, "HIV Vaccines: Prospects and Challenges," Scientific American, pp 78-83 (July 1998) | |
| | | Feng, Yu et al, "HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven- Transmembrane, G Protein-Coupled Receptor," Science, 272, 872-877 (1996) | |
| | | Bleul, Conrad C. et al, "The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry," Nature, 382, 829 -831 (1996) | |
| | | Schols, Dominique et al, "Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4," J. Exp. Med., 186, 1383 - 1387 (1997) | |

| | | |
|-----------|------------|--|
| Examiner | Date | |
| Signature | Considered | |
| | | |

"EXAMINET: Irritar transcessors and the properties of the properti symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, OPF1 OF DOCKS an application. Combining by Systemic VP. 3 of Sci. 12.2 in the USPTO. The Mis Vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or system of reducing the burlen, should be sent to the Chief Information Officer, U.S. Pattern Trademark Office, P.O. Box 1450 Metanding, Va. 2213-13.0 in ON SEND FEED RES DROWNETED FORMST OT INS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

105917@2/se@Alds-06626

Receipt date: 09/26/2007 Approved for use through 03/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| Un | nder the Paperwork Ren | duction. | Act of 1995, no persons are | required to respond to a collection of infe | ormation unless it contains a valid OMB control number |
|--|-------------------------|----------------------|-----------------------------|---|--|
| C | h-414 do 600 forms 4 44 | 40/DTC | | Comp | plete if Known |
| Sui | DStitute for form 144 | 19/210 | ' | Application Number | 10/591,722 |
| INI | FORMATION | I DIS | CLOSURE | Filing Date | |
| Under the Paperwork Reduction Act of 1995, no persons Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 4 of 4 | | First Named Inventor | Atsushi SAITOU | | |
| | | | | Group Art Unit | |
| (| use as many she | ets as | necessary) | Examiner Name | |
| Sheet | 4 | of | 4 | Attorney Docket Number | MOEG-P100 |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|---|----|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| | | Murakami, Tsutomu et al, "A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line- tropic HIV-1 Infection," J. Exp. Med., 186, 1389 - 1393 (1997) | |
| | | Doranz, Benjamin J. et al, "A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor," J. Exp. Med., 186, 1395 - 1400 (1997) | |
| | | Muller, Anja et al, "Involvement of chemokine receptors in breast cancer metastasis," Nature, 410, 50-56 (2001) | |
| | | | |
| | | | |
| | | 1 | |
| | | | |
| | | | |

| Examiner Signature | /Samantha Shterengarts/ | Date Considered | 08/26/2009 |
|-----------------------|-------------------------|--------------------|------------|
| Oignature | | Considered | 00/L0/L000 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the includion of the year of the reging of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols es indicated on the document under WIPO Standard ST. 16 (possible. *Application to place a check mark here it Englanguage translation is statched.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) en application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, Including gathering, preparing, and submitting the compileted application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compile this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandriqs, V.A. 2231-4350, D.N. OT SEND FEES OR COMPILETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.